Phillip Broadwith
As Business editor, my aim is to highlight to readers the exciting and innovative chemistry going on in the commercial sector, as well as keeping you abreast of trends and developments in the world of chemistry businesses.
From the point I left school, my aim was to join the pharmaceutical industry. A gap year and summer placements in company labs, and a PhD in organic synthesis followed.
But halfway through my PhD I entered a writing competition run by the Daily Telegraph. I managed to win – somewhat to my own surprise. That changed my perspective and made me think that I should consider writing more seriously as a career. I joined the Royal Society of Chemistry just before submitting my thesis, and luckily a position with Chemistry World came up a few months later. I sometimes miss the thrills (less so the spills) of lab work, but interacting with world-leading scientists and industrialists, as well as learning new things on a daily basis more than makes up for it.
Contact Info
- Email:
- broadwithp@rsc.org
OpinionAugmented intelligence
Robots will increasingly work alongside humans to solve complex problems
BusinessMallinckrodt settles US opioid lawsuit
Firm will pay $35m over allegations it failed to report suspicious orders of controlled substances
BusinessEU to investigate Merck KGaA’s merger with Sigma–Aldrich
Commission says Merck failed to disclose a crucial research project
BusinessCelgene and BeiGene agree cancer partnership
Immuno-oncology deal sees firms exchange licensing rights for antibody drugs
OpinionWhat's holding back continuous manufacturing?
Despite manay advantages, the move to flow chemistry in fine and speciality chemicals is slow
BusinessGM corn growers win US lawsuit against Syngenta
Kansas jury awards over $217m damages to farmers in the first of eight trials
BusinessJ&J licenses Protagonist’s inflammatory bowel peptide
Potential first-in-class treatment is just about to enter clinical trials
BusinessExplosion kills 10 at Chinese petrochemical plant
Nine others injured when gas tanker exploded in loading area
BusinessIneos expands North Sea oil and gas operations
Purchase of Danish Dong Energy and BP’s Forties pipeline will feed Grangemouth refinery
OpinionDrug pricing must be more transparent
Pricing is a complex issue - how can we make it clearer?
BusinessSeattle Genetics cancels Immunomedics deal
Settlement also resolves disputes with shareholders
BusinessPatheon buyout brings Thermo into contract manufacturing
$7.2bn deal expands Thermo Fisher’s laboratory products and services segment
BusinessAvantor to buy VWR for $6.4bn
Deal continues trend of consolidation in laboratory supplies sector
BusinessBP to sell Chinese joint venture stake to Sinopec
Oil giant retains significant investment in China, but is shifting focus
BusinessChina approves BMS’s hepatitis C drugs
Combination is first all-oral treatment in China, where Gilead’s Sovaldi is not yet approved
OpinionBuilding business across borders
Internationality is here to stay. Companies need to capitalise on it
BusinessFresenius to buy Akorn and Merck KGaA’s biosimilars
Deals give Fresenius entry into rapidly growing biological drugs market
BusinessJob cuts at Amgen, Takeda and Vertex
Takeda reorganising following Ariad takeover, while Amgen and Vertex move staff to Cambridge and San Francisco hubs
BusinessJob cuts at Takeda, Boehringer and Arena
Hundreds of positions eliminated as companies re-evaluate R&D
BusinessCelgene and Jounce team up against cancer
Firms promise next-generation immuno-oncology as existing drugs rack up successes
